Patents Reveal New Prodrugs For Psilocin, Promising Reliable Mental Health Treatments
Recent innovations in psychedelics research are laying the groundwork for a potential breakthrough in mental health treatments. The focus is on three new compounds patented by CaaMTech, Inc., designed to address the limitations of traditional psychedelics such as psilocybin and psilocin.
According to a patent review published by the American Chemical Society, the new compounds promise improved stability, bioavailability and therapeutic efficacy for conditions such as depression, anxiety and substance use disorders.
Revolutionizing Psilocin Delivery: A New Approach
A groundbreaking patent, US 2023/0406823 A1, introduces a new compound called 4-pivaloyloxy-N-methyltryptammonium chloride, designed to solve some of the biggest challenges in using psilocin for therapeutic purposes. Psilocin, a chemical related to psilocybin, the psychoactive compound in magic mushrooms, affects mood, perception and cognition by interacting with serotonin receptors in the brain. However, psilocin is unstable, which has limited its use in medicine.
The key innovation here is a stable form of psilocin that, when taken, is gradually broken down into active psilocin in the body. This prodrug allows for a controlled release of its effects, making it easier to use in medical treatments. Early studies show that this new compound is more stable and easier for …